All 1 tracked stories fall under one category: clinical-trial. CDC National Center for Injury Prevention and Control is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. ICD-10 appears in 1 tracked Biotech story from August 7, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about ICD-10
All 1 tracked stories fall under one category: clinical-trial. CDC National Center for Injury Prevention and Control is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. ICD-10 appears in 1 tracked Biotech story from August 7, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 7 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering ICD-10. Shared-story counts are live from our verified record — not editorial picks.
With 2.75 million suffering from cannabis hyperemesis syndrome and a 16% jump in ED diagnoses after a new ICD code, an underserved patient population emerges. Biopharma companies can explore targeted therapies for CHS, a condition currently managed only with abstinence and supportive care, presenting a significant unmet medical need.